BG505 SOSIP 664 gp140 adjuvanted vaccine (GlaxoSmithKline/International AIDS Vaccine Initiative)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameBG505 SOSIP 664 gp140 adjuvanted vaccine (GlaxoSmithKline/International AIDS Vaccine Initiative)
Drug Alias NameBG505 SOSIP.664 gp140 adjuvantedBG505 SOSIP.664 gp140 Vaccine
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Genetically engineered subunit vaccine
Mechanisms of ActionImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNetherlands
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesInternational Aids Vaccine Initiative
China Registration ClassN/A

Develop Information

Active CompaniesInternational Aids Vaccine InitiativeNational Institute Of Allergy And Infectious Diseases (Niaid)
Inactive CompaniesN/A
Active IndicationsHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A